Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.

ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.

Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.

Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Tadalafil and Finasteride may help treat aggressive melanoma.

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.

NFATc1 controls hair stem cell activity, affecting hair growth and could be a target for hair loss treatments.

NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.

Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.

Early diagnosis and comprehensive management improve life quality for Netherton syndrome patients.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

Repurposing existing drugs can improve cancer treatment but faces challenges.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

Hair growth supplements do not reduce the effectiveness of the breast cancer treatment tamoxifen.

Ritlecitinib may help young adults with severe alopecia areata when ketoconazole doesn't work.

Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.

ITK inhibitors may effectively treat alopecia areata.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.